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A report on the eighth annual meeting of the Human
Genome Organization (HGM2003), Cancun, Mexico, 27-30
April 2003. 
The eighth annual Human Genome Organization (HUGO)
meeting was a very special one, starting as it did two days
after the 50th anniversary of the discovery of the structure of
DNA by James Watson and Francis Crick and soon after the
announcement of the completion of the human genome
sequence to 99% accuracy. The meeting covered a vast range
of topics, including medical genomics, pharmacogenomics,
stem-cell genomics, comparative genomics, genome varia-
tion and diversity, model organisms, functional annotation
of genomes, proteomics, transcriptomics, new technologies,
bioinformatics, and ethical issues. Given the scope and the
number of parallel sessions, it is possible to give only a
partial illustration here of the ideas and results presented.
A special session was devoted to celebrating the history of
the human genome and thinking about the future. Victor
McKusick (Johns Hopkins University School of Medicine,
Baltimore, USA) reminded us that it was also the 15th
anniversary of HUGO and the 30th of the human genome
mapping initiatives. ‘Genome’, as we learned, is a word
coined in 1920 by Hans Winkler in Germany, putting
together ‘gene’ with ‘chromosome’. The precise number of
human chromosomes - 46, not 48 as was previously thought
- was established in a meeting in Copenhagen as recently as
1956. The human genome is giving the foundation for a neo-
Vesalian basis for medicine, beyond the conventional
modern medicine that started with the first complete text-
book of human anatomy by Andreas Vesalius in 1543.
The sequencing of the human genome was an effort of 16
laboratories in 6 different countries. Francis Collins
(National Human Genome Research Institute, National
Institutes of Health (NIH), Bethesda, USA) acknowledged
the people present at the meeting who had been involved in
the sequencing, and then summarized future goals in
genomics and its potential contributions to biology, health
and society. Biology will benefit from genomics through the
generation of haplotype maps (which show correlations
between nearby polymorphisms), the sequencing of many
more genomes, new expression technologies, the identifica-
tion of all functional sequence elements, and the develop-
ment of computational models of the cell. Reducing the cost
of sequencing a mammalian genome to a few thousand
dollars seems attainable. The potential benefits of genomics
to human health that Collins put forth include no less than
the identification of the genetic and environmental factors
involved in all diseases, the development of ‘sentinel’ systems
for early detection of disease, and the ability to perform high-
throughput screens using specific small-molecule agonists
and antagonists for every human protein. At the level of
society, genomics raises ethical questions about privacy
against genetic discrimination and the need for precise defi-
nitions for regulating reproductive cloning, and it also gives
us a new understanding of the genetic differences between
groups of human beings in history. The lesson that Collins
drew from this summary was that if you want to get things
done you should make big plans, not little ones. 
Medical genomics 
It was clear from the meeting that genomics has the poten-
tial to revolutionize medical knowledge and, eventually,
medical practice, particularly through the identification ofgenes conferring susceptibility to common diseases. We
learned about the identification of novel gene products
linked to common disorders and how they relate to biologi-
cal processes leading to disease. In the case of diabetes, the
calpain family of calcium-activated cysteine proteases have
been found to be  involved in a variety of cellular functions
including regulation of intracellular signaling and apoptosis
(Graeme Bell, University of Chicago, USA). For systemic
lupus erythematosus (SLE), an intronic polymorphism in the
immunoreceptor PDCD1 was found to be associated with the
disease (Ludmila Prokunina, Uppsala University, Sweden).
This polymorphism alters the binding site of the transcrip-
tion factor Runx-1, which could lead to aberrant regulation
of the PDCD1 gene, contributing to the deregulated self-tol-
erance characteristic of SLE.
Stephen W. Scherer (Hospital for Sick Children, Toronto,
Canada) described the integration of functional and struc-
tural maps of human chromosome 7, leading to the discovery
of genes responsible for diseases such as holoprosencephaly,
distal tubular renal acidosis, type II citrullinemia, hereditary
papillary renal carcinoma, and more. Holoprosencephaly is a
genetically heterogeneous disorder causing brain and
craniofacial defects; papillary renal carcinoma is an domi-
nant hereditary form of renal carcinoma characterized by
multiple bilateral papillary renal tumors; distal tubular renal
acidosis is a recessive disorder causing kidney failure; and
type II citrullinemia is associated with a decreased activity of
the enzyme argininosuccinate synthetase in liver, which can
cause disorientation or a coma.
The annotation of genes, including their splicing patterns,
and the precise position of their promoters, has been made
more successful by isolating full-length capped cDNAs, as
explained by Sumio Sugano (Human Genome Center, Uni-
versity of Tokyo, Japan). By taking advantage of the
common origin of most of the population living in Quebec,
which means that people with the same genetic disease are
likely, through shared ancestry, to carry the same allele,
Thomas Hudson (McGill University, Toronto, Canada) is
trying to identify haplotype blocks that are overrepresented
in individuals with multifactorial diseases such as asthma
and coronary heart disease. Although some large haplotype
blocks have been found around alleles of recessive disease
genes, these were not found for the multifactorial diseases.
Gerardo Jiménez-Sánchez (Institute of Genetic Medicine,
Baltimore, USA) described current progress on the annota-
tion of the ‘Human Disease Genome’ and presented a list of
900 genes obtained so far.
Zhu Chen (Chinese National Human Genome Center,
Shanghai, China) presented recent advances in parasite
genomics. By sequencing expressed sequence tags and
comparing them with genes from other species, he showed
that the trematode parasite Schistosoma japonicum encodes
receptors for signals from hosts such as insulin, proges-
terone, and others; this ‘molecular mimicry’ is likely to be a
strategy used to escape the host immune system. This
approach allowed the identification of possible targets for
new drugs against schistosomiasis.
Functional genomics and bioinformatics
Mike Tyers (University of Toronto, Canada) illustrated the
complexities involved in the assignment of functions to
genes, especially when genetic perturbations cause weakly
discernable phenotypes. Cell-size homeostasis in yeast gives
one example of this problem - the genes involved are hard to
find because cell-size defects often cause little or no growth
defect. His group has applied multiple functional genomic
approaches (proteome, transcriptome, and roboticized syn-
thetic genetic arrays) to the study of this problem in yeast.
He has found that deletions in 15 ribosome-biogenesis
factors give mutant cells that are abnormally small. Many of
the genes encoding these factors are regulated by a tran-
scription factor (Sfp1p), which, when deleted, also gives very
small cells. These approaches reveal a plausible link between
ribosome-biogenesis factors and the cell-cycle machinery
and also identify new genes that might regulate the trigger-
ing of cell division in late G1 phase.
The genetic and molecular basis for phenotypic variation is
still largely unknown. In a talk by Leif Andersson (Uppsala
University, Sweden) we heard about what was claimed to be
the first identification of a single point mutation underlying
a quantitative trait locus (QTL). By comparing wild boars
and the Large White breed of domestic pig, Andersson and
colleagues showed that a QTL that increases muscle growth,
decreases fat deposition and increases the weight of the
heart in domestic pigs is attributable to a regulatory muta-
tion that increases postnatal expression of insulin-like
growth factor 2 in skeletal muscle.
A very good overview of chromatin structure and its role in
gene regulation was given by Carl Wu (National Cancer
Institute, NIH, Bethesda, USA). He introduced us to a land-
scape of short linker regions between nucleosomes - of 20 to
60 base pairs - which are dynamically made available to the
transcription machinery. Four different classes of ATP-
dependent chromatin-remodeling machines catalyze the
movement of nucleosomes. During chromatin remodeling,
histone octamers remain on the DNA; their sliding is
thus required in the regulated activation or repression of
many genes.
Methylation of CpG islands - which are found upstream of
many genes - is regulated by the methyl-CpG-binding domain
(MBD) family of transcriptional regulators. In Rett syn-
drome, a disease unique to females, brain retardation has
been found to correlate with lack of expression in the brain of
MECP2 (a member of the MBD family), even when the
protein is expressed in other tissues. Tim Roloff (Max Planck
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new members of the MBD family and proposed that, in
tissues other than the brain, these proteins must compensate
this lack of expression of MECP2 in Rett syndrome patients. 
Alicia González (Universidad Nacional Autónoma de
México (UNAM), Mexico City, Mexico) described detailed
studies of co-regulated divergent promoters in yeast, a fre-
quent type of organization in this organism. The glutamate
synthase gene GLT1 is expressed from a promoter that is
divergent from that of UGA3, which encodes a transcrip-
tional activator of gamma aminobutyric acid (GABA)-
dependent genes, but GLT1 is expressed at 10-fold higher
levels than UGA3. This difference is partly due to a binding
site for the activator ARS-binding factor (Abf1p); binding of
Abf1p causes a peculiar chromatin organization that stimu-
lates GLT1 and represses UGA3. The directional effect on
the expression of these two promoters is unique to this acti-
vator, even though both genes are subject to control by
three more factors. 
Alberto Kornblihtt (University of Buenos Aires, Argentina)
described progress in understanding how alternative mRNA
splicing is modified by alterations in the rate of transcrip-
tional elongation by RNA polymerase II. Kornblihtt has pre-
viously shown that transcription and splicing are coupled;
differential splicing of exons is affected by the elongation
rate, which in turn depends on the transcriptional promoter.
Some viral transcriptional activators, such as VP16, increase
exon skipping, whereas others, such as large T antigen,
decrease it. Kornblihtt explained that fast elongation with no
pausing will naturally increase the likelihood that exons are
skipped, but only if there are regulatory sites for alternative
splicing in the gene; and a single mutation can lead to the
inclusion of exons, independent of the rate of elongation. In
a human cell line, a mutated RNA polymerase II was shown
to lead to increased inclusion of exons.
Minoru Ko (National Institute on Aging, NIH, Bethesda, USA)
has made a comprehensive catalog of genes expressed in
mouse embryonic and adult stem cells as well as in unfertilized
eggs and blastocysts [http://lgsun.grc.nia.nih.gov/cDNA/
cDNA.html]. This cDNA collection provides alternatively
spliced forms for more than 3,400 genes that have previ-
ously been described, and at least 1,450 novel genes were
found. A microarray made from about 22,000 of these
sequences has been constructed, which may give insights
into the fundamental biology of stem cells. 
The problem of finding syntax and query languages with
which to manage the various biological databases has been
tackled by the community with the development of ‘Gene
Ontology’ (GO), arising out of Monica Riley’s functional clas-
sification of genes in Escherichia coli. Michael Ashburner
(Cambridge University, UK) described how GO is gradually
expanding to many other areas of biological interest, such as
anatomy, pathology, and phenotypic data. And John Matese
(Stanford University, USA) presented a unified computational
genomic resource, ‘Source’, that facilitates searching, analyzing
and interpreting data of microarray experiments in yeast
[http://source.stanford.edu/]. 
Rosa María Gutiérrez (UNAM, Morelos, Mexico) has analyzed
the congruence between microarray data and current
knowledge of regulatory networks in E. coli. She showed
that the consistency ranges from 40% to 80%, depending on
the type of information and the experimental conditions
used. This analysis provides a new perspective, differing
from that gained from clustering analyses, that will help us
to understand how regulatory networks determine expression
of the genes detected by microarray expression profiles.
Finally, Yoshiyuki Sakaki (RIKEN, Yokohama, Japan), the
current president of HUGO, concluded that with the oppor-
tunity to compare other complete genomes (such as that of
the chimpanzee) with the human genome sequence, as well
as information on differential expression of genes in differ-
ent tissues, a new research period of outstanding structural,
functional and evolutionary discoveries lies ahead. Abstracts
of the meeting are freely available online [http://hgm2003.
hgu.mrc.ac.uk] and the next HUGO meeting will be held in
Berlin, Germany, in April 2004.
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